Abstract:Cancers figure among the leading causes of morbidity and mortality worldwide. The number of new cases is expected to rise by about 70% over the next 2 decades. Development of novel therapeutic agents is urgently needed for clinical cancer therapy. Alphavirus M1 is a Getah-like virus isolated from China with a genome of positive single-strand RNA. We have previously identified that alphavirus M1 is a naturally existing oncolytic virus with significant anticancer activity against different kinds of cancer (e.g., liver cancer, bladder cancer, and colon cancer). To support the incoming clinical trial of intravenous administration of alphavirus M1 to cancer patients, we assessed the safety of M1 in adult nonhuman primates. We previously presented the genome sequencing data of the cynomolgus macaques (Macaca fascicularis), which was demonstrated as an ideal animal species for virus infection study. Therefore, we chose cynomolgus macaques of either sex for the present safety study of oncolytic virus M1. In the first round of administration, five experimental macaques were intravenously injected with six times of oncolytic virus M1 (1 x 10(9) pfu/dose) in 1 week, compared with five vehicle-injected control animals. The last two rounds of injections were further completed in the following months in the same way as the first round. Body weight, temperature, complete blood count, clinical biochemistries, cytokine profiles, lymphocytes subsets, neutralizing antibody, and clinical symptoms were closely monitored at different time points. Magnetic resonance imaging was also performed to assess the possibility of encephalitis or arthritis. As a result, no clinical, biochemical, immunological, or medical imaging or other pathological evidence of toxicity was found during the whole process of the study. Our results in cynomolgus macaques suggested the safety of intravenous administration of oncolytic virus M1 in cancer patients in the future.

Visualization of the Oncolytic Alphavirus M1 Life Cycle in Cancer Cells

Real-Time Visualization And Quantification Of Oncolytic M1 Virus In Vitro And In Vivo

Identification and Characterization of Alphavirus M1 As a Selective Oncolytic Virus Targeting ZAP-defective Human Cancers.

Systematic Characterization of the Biodistribution of the Oncolytic Virus M1

Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1.

Suppression of CCDC6 sensitizes tumor to oncolytic virus M1

Alphavirus M1 induces apoptosis of malignant glioma cells via downregulation and nucleolar translocation of p21WAF1/CIP1 protein.

Liposome Encapsulation of Oncolytic Virus M1 to Reduce Immunogenicity and Immune Clearance in Vivo.

[Advances in Measles Virus for Cancer Therapy].

Tumors Driven by RAS Signaling Harbor a Natural Vulnerability to Oncolytic Virus M1

Biodistribution and Kinetics of the Novel Selective Oncolytic Adenovirus M1 after Systemic Administration

Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus

Naturally Existing Oncolytic Virus M1 is Nonpathogenic for the Nonhuman Primates after Multiple Rounds of Repeated Intravenous Injections

Selective Replication of Oncolytic Virus M1 Results in a Bystander Killing Effect That is Potentiated by Smac Mimetics

Alphavirus M1 Induces Apoptosis of Malignant Glioma Cells Via Downregulation and Nucleolar Translocation

Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC

Oncolytic Vaccinia Virus Inhibits Human Hepatocellular Carcinoma Mhcc97-H Cell Proliferation Via Endoplasmic Reticulum Stress, Autophagy and Wnt Pathways

Selective antagonism of Bcl-xL potentiates M1 oncolysis by enhancing mitochondrial apoptosis.

Targeting Vcp Enhances Anticancer Activity Of Oncolytic Virus M1 In Hepatocellular Carcinoma

Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer

DNA-PK Inhibition Synergizes with Oncolytic Virus M1 by Inhibiting Antiviral Response and Potentiating DNA Damage